Clinical

Canagliflozin protects diabetic kidneys


 

Background: Type 2 diabetes is the leading cause of kidney failure worldwide. Few treatment options exist to help improve on this outcome in patients with chronic kidney disease.

Dr. Matthew Hoegh, a hospitalist at the University of Colorado at Denver, Aurora

Dr. Matthew Hoegh


Study design: CREDENCE (industry-sponsored) double-blind, randomized placebo-controlled trial.

Setting: 695 sites in 34 countries, 4,401 patients.

Synopsis: The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. Canagliflozin reduced serious adverse renal events or death from renal or cardiovascular causes at 2.62 years (11.1% vs. 15.5% with placebo; number needed to treat, 23).Bottom line: Canagliflozin lowered serious adverse renal events people with type 2 diabetics who also had chronic kidney disease.

Citation: Perkovic V et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019 Apr 14. doi: 10-1056/NEJMoa1811744.

Dr. Hoegh is a hospitalist at the University of Colorado at Denver, Aurora.

Recommended Reading

For COVID-19 plus diabetes, glycemic control tops treatment list
The Hospitalist
DAPA-HF: Dapagliflozin slows T2D onset in heart failure patients
The Hospitalist
Where does dexamethasone fit in with diabetic ketoacidosis in COVID-19?
The Hospitalist
Cortisol levels on COVID-19 admission may be a marker of severity
The Hospitalist
Dapagliflozin benefits low-EF heart failure regardless of diuretic dose: DAPA-HF
The Hospitalist
   Comments ()